Epidermodysplasia Verruciformis Pathology

Epidermodysplasia verruciformis (EV) is a rare genodermatosis characterized by abnormal susceptibility to specific human papillomavirus (HPV) types, leading to persistent warty lesions and a high risk of cutaneous squamous cell carcinoma (SCC).

Introduction

Epidermodysplasia verruciformis, first described by Lewandowsky and Lutz in 1922, manifests as widespread, refractory flat warts and reddish plaques, primarily due to beta-HPV infections. The condition arises from genetic defects impairing immune control of HPV, resulting in chronic infections that often progress to malignancy in sun-exposed areas. This pathology overview details histological features, clinical variants, and oncogenic risks essential for dermatologists and pathologists.

Clinical Features

EV presents in childhood with polymorphic lesions: flat-topped papules, pityriasis versicolor-like macules, and seborrheic keratosis-like plaques, predominantly on sun-exposed sites such as face, neck, hands, and extremities. Lesions evolve from hypopigmented or red-brown macules to verrucous plaques, with 30-60% progressing to SCC by ages 30-50.

• Flat wart-like lesions: Small, pinkish-red papules on hands, feet, and face, resembling plane warts.
• Plaque-type lesions: Scaly, tan-brown patches on trunk, mimicking tinea versicolor.
• Seborrheic keratosis-like: Stuck-on, warty growths on forehead and neck.
• Malignant transformation: Indurated, hyperkeratotic nodules in 60% of cases.

Histopathology

Microscopic examination reveals distinctive features confirming EV. The epidermis shows massive acanthosis, hypergranulosis, and hyperkeratosis with a church-spire pattern of parakeratosis. Hallmark clear cells—keratinocytes with abundant pale, vacuolated cytoplasm and perinuclear halo—are present throughout all epidermal layers, indicating HPV cytopathic effect.

Additional findings include:

• Blue-grey pallor in upper epidermis due to keratohyalin granules.
• Absent or minimal dermal inflammation.
• Binucleate cells and koilocytes in milder cases.

Immunohistochemistry

IHC demonstrates HPV antigens in clear cells, with p16 positivity in dysplastic lesions indicating viral oncoprotein activity. Ki-67 proliferation index is elevated in upper epidermis, contrasting typical warts. Beta-HPV L1 capsid protein is detectable via PCR or in situ hybridization in non-malignant lesions.

Cytogenetics and Molecular Pathology

EV stems from biallelic mutations in EVER1 (TMC6) or EVER2 (TMC8) genes on 17q25, disrupting zinc homeostasis and keratinocyte HPV restriction. EVER proteins form the TMC6/TMC8 complex, preventing viral entry. Mutant keratinocytes fail to degrade viral genomes, enabling persistent replication.

Secondary mutations include RHOH, MST1 deficiency, and LCK splicing defects in EVER-wildtype cases. Beta-HPV (types 5,8,20) integrate sporadically, cooperating with UV-induced p53 mutations for oncogenesis.

Electron Microscopy

Ultrastructurally, virions (50 nm, non-enveloped) fill clear cell cytoplasm. Condensed keratohyalin aggregates around nuclei, with disrupted desmosomes in dysplastic areas. These findings distinguish EV from common warts, where virions cluster in granular layers.

Pathogenesis

Defective EVER1/2 impairs CORF (cholesterol-dependent regulation of oncoproteins), allowing beta-HPV E5/E6 to evade apoptosis and promote proliferation. UV exposure exacerbates this by activating viral promoters and inducing DNA damage, synergizing with HPV oncogenes for SCC. Immune evasion via downregulated MHC-I explains lesion refractoriness.

Progression to Malignancy

Approximately 50% of EV patients develop multiple cutaneous SCCs, Bowen disease, or basal cell carcinomas in sun-exposed sites. Malignant lesions show full-thickness atypia, keratin pearl formation, and invasion. Risk factors include fair skin, chronic UV exposure, and polymorphic lesions.

Diagnosis

Diagnosis integrates clinical morphology, histopathology (clear cells), HPV typing (beta-genus), and genetic testing (TMC6/8 sequencing). Differential includes flat warts, pityriasis versicolor, porokeratosis, and actinic keratosis.

Treatment and Management

No cure exists; management targets lesions and cancer prevention. Systemic retinoids (acitretin 0.5-1 mg/kg/day) reduce proliferation. Topical therapies: imiquimod, 5-FU, PDT. Surgical excision for suspicious nodules, with lifelong sun protection.

• Retinoids: Antiproliferative, best long-term option.
• Interferons: Enhance immunity with retinoids.
• Cimetidine: Variable efficacy via T-cell modulation.
• Surveillance: Annual dermatologic exams.

Frequently Asked Questions (FAQs)

Q: What causes epidermodysplasia verruciformis?

A: Primarily germline mutations in EVER1/EVER2 genes causing HPV susceptibility.

Q: Is EV contagious?

A: No, but HPV transmission can occur; it’s genetically determined.

Q: Can EV be cured?

A: No curative treatment; lifelong management required.

Q: What is the cancer risk in EV?

A: 30-60% lifetime risk of SCC.

Q: How is EV diagnosed pathologically?

A: By clear cells, church-spire keratosis on biopsy.

Similar Articles

Alarming Rise in Self-Harm in Young People

Alarming Rise in Self-Harm in Young People

Skin Signs Of Non-Accidental Injury: Expert Guide For Clinicians

Lichen Simplex Of The Scrotum: Diagnosis And Treatment

Labial Adhesion In Prepubertal Girls: What Parents Need To Know

Thrush In Men: 5 Signs, Causes, And Treatment Options

Author

Sneha TeteBeauty & Lifestyle Writer

 

Sneha is a relationships and lifestyle writer with a strong foundation in applied linguistics and certified training in relationship coaching. She brings over five years of writing experience to renewcure,  crafting thoughtful, research-driven content that empowers readers to build healthier relationships, boost emotional well-being, and embrace holistic living.

Read full bio of Sneha Tete